05.08.2016 MediClin AG  DE0006595101

DGAP-News: MediClin AG: Group sales and Group operating result of the first half year of 2016 are significantly above the same period of the previous year


 
DGAP-News: MediClin AG / Key word(s): Half Year Results MediClin AG: Group sales and Group operating result of the first half year of 2016 are significantly above the same period of the previous year 05.08.2016 / 17:09 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- MediClin: Group sales and Group operating result of the first half year of 2016 are significantly above the same period of the previous year Offenburg, August 5, 2016 - In the first six months of 2016, MEDICLIN Aktiengesellschaft (MediClin) achieved Group sales of EUR 289.2 mill. (H1 2015: EUR 274.2 mill.) thus being up EUR 15.0 mill. or 5.5 % above the value of the first six months of 2015. The occupancy rate was 88.3 % (H1 2015: 87.4 %). The Group operating result showed a further improvement of EUR 2.5 mill. up to EUR 9.1 mill. (H1 2015: EUR 6.6 mill.). Sales increase in the post-acute and acute segment and in the business area nursing care In the post-acute segment sales amounted to EUR 172.6 mill and were EUR 11.0 mill. higher than in the same period of the previous year. This growth was driven by the good utilisation of capacities in neurology, acute neurology, psychosomatics, orthopaedics and geriatrics. The post-acute segment result rose by EUR 3.2 mill. to EUR 9.0 mill. In the acute segment sales of EUR 107.4 mill were achieved. The sales increase of EUR 3.4 mill. was generated primarily in the second quarter of 2016. The segment result of EUR 4.2 mill. was EUR 1.0 mill. below the previous year's value due to a rise in personnel and material expenses. Sales in the nursing care business area were up EUR 0.4 mill. to EUR 7.2 mil. on the back of an improvement of the occupancy rate by 1.1 percentage points. In the first six months of 2016, EUR 13.7 mill. (gross) was invested, thereof financed with subsidies EUR 2.1 mill. (H1 2015: EUR 12.6 mill. thereof with subsidies EUR 1.1 mill.). Cash and cash equivalents as of 30 June 2016 amounted to EUR 21.6 mill. (30.06.2015: EUR 18.0 mill.). The equity ratio was 50.0 % (30.06.2015: 48.1 %). MediClin employed an average of 6,573 employees, calculated on the basis of full-time staff, in the first six months of 2016 (H1 2015: 6,492 full-time employees). Existing syndicate loan successfully refinanced Before the termination of the existing syndicate loan of originally EUR 60 mill. concluded on 13 February 2012 (book value as of 29.07.2016: EUR 30 mill.) a new syndicate loan amounting again to EUR 60 mill. was concluded in an attractive interest rate environment and to sustainably favourable conditions. The loan has a maturity of five years plus two renewal options of one year each. EUR 30 mill. thereof are designated to refinance the original syndicated loan. The other EUR 30 mill. refer to a revolving loan that can be drawn to finance the development of strongly requested medical and therapeutic specialist fields. The improved conditions will show a positive effect on the financial result. Outlook The business development in the first six months of 2016 indicates that the sales and earnings targets for the Group can be achieved. This applies to the post-acute segment; in the acute segment, the Management Board assumes that the forecast sales growth will be reached and that the segment result will be at the lower end of the forecast range due to higher expenses. The interim report as of 30 June 2016 is available under www.mediclin.de in German and English. Key figures and yoy comparison for the Group and the segments

in million EUR                              H1 2016               H1 2015
Group
Group sales                                   289.2                 274.2
Raw materials and consumables                  53.6                  51.3
used
Staff costs                                   171.0                 164.0
Depreciation and amortisation                   9.3                   9.0
Other operating expenses                       50.0                  46.9
Group operating result                          9.1                   6.6
Total consolidated result                       6.3                   4.3
attributable to shareholders
Cash flow from operative                        5.0                   3.9
activities
Earnings per share in EUR                      0.13                  0.09
(un-/diluted)
Number of employees  (full                    6,573                 6,492
time staff on average)

Post-acute
Sales                                         172.6                 161.6
Segment result                                  9.0                   5.8
Acute
Sales                                         107.4                 104.0
Segment result                                  4.2                   5.2
Other activities and
reconciliation
Sales                                           9.2                   8.6
thereof business area nursing                   7.2                   6.8
care
Segment result                                 -4.1                  -4.4
(Due to arithmetical reasons, calculation differences may occur in the
table above)


About MediClin AG (Ticker: MED; WKN: 659 510) MediClin AG is a nation-wide clinic operator and large provider of services in the area of Psycho- and Neuro-sciences as well as Orthopaedic. With 34 clinics, 7 nursing care facilities and 8 medical care centres in 11 federal states MediClin has a total capacity of approximately 8,000 beds. MediClins' facilities include acute care clinics, i.e., general hospitals, special treatment facilities, specialised hospitals and clinics for post- acute treatment and medical rehabilitation. MediClin has approximately 9,000 employees. MediClin ─ a company of the Asklepios Group --------------------------------------------------------------------------- 05.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: MediClin AG Okenstraße 27 77652 Offenburg Germany Phone: +49 (0)781 488-326 Fax: +49 (0)781 488-184 E-mail: [email protected] Internet: www.mediclin.de ISIN: DE0006595101 WKN: 659510 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 490041 05.08.2016


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 609,08 645,11 673,09 659,86 673,14 704,70 730,07
EBITDA1,2 27,01 37,35 93,58 77,50 85,22 90,92 98,73
EBITDA-Marge3 4,43 5,79 13,90 11,74 12,66 12,90
EBIT1,4 6,62 15,06 22,41 0,15 11,56 19,52 12,72
EBIT-Marge5 1,09 2,33 3,33 0,02 1,72 2,77 1,74
Jahresüberschuss1 3,96 7,76 9,68 -0,04 1,49 9,72 -10,72
Netto-Marge6 0,65 1,20 1,44 -0,01 0,22 1,38 -1,47
Cashflow1,7 19,34 29,77 69,59 118,69 81,97 34,64 78,00
Ergebnis je Aktie8 0,08 0,16 0,20 -0,19 0,03 0,20 -0,23
Dividende8 0,05 0,05 0,05 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Mediclin
WKN Kurs in € Einschätzung Börsenwert in Mio. €
659510 2,540 Halten 120,65
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
9,77 19,17 0,51 19,10
KBV KCV KUV EV/EBITDA
0,62 1,55 0,17 1,42
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,00 0,00 0,00 06.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
02.05.2024 31.07.2024 04.11.2024 26.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-1,70% -7,70% -7,30% -25,29%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu MediClin AG  ISIN: DE0006595101 können Sie bei EQS abrufen


Pflegeeinrichtungen , 659510 , MED , XETR:MED